Background: The phase III MPACT trial demonstrated the superiority of gemcitabine (Gem) combined with Nab-paclitaxel (Nab-P) versus gemcitabine alone in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to evaluate the effect of Gem/Nab-P in routine clinical practice.
Methods: From January 2015 to December 2018, patients with metastatic PDAC receiving firstline treatment with a combination of gemcitabine and Nab-paclitaxel were included in a multicentre retrospective observational study. Exploratory analyses of efficacy, and prognostic and predictive markers, were performed.
Results: The cohort comprised 115 patients (median age 65 [range 50-84] years) with good performance status (ECOG PS 0-1). The median overall survival (OS) was 11 months (95% CI; 9-13) and the median progression-free survival (PFS) was 6 months (95% CI 5-7). Partial response and stable disease were achieved in 44 and 30 patients, respectively, yielding an overall disease control rate (DCR) of 64.3%. Grade 3-4 hematological toxicity frequency was 22.61% for neutropenia, 5.22% for anemia, and 3.48% for thrombocytopenia. Grade 3 asthenia was recorded in 2.61% of patients. No grade 4 non-hematological events were reported. Dose reduction was necessary in 51.3% of the patients.
Conclusion: Our results confirm the efficacy and safety of a first-line regimen comprising gemcitabine and Nab-paclitaxel in metastatic PDAC in a real-life population.
[http://dx.doi.org/10.1016/j.ejca.2018.07.005] [PMID: 30100160]
[http://dx.doi.org/10.1002/cncr.22852] [PMID: 17580363]
[http://dx.doi.org/10.1200/JCO.1922.214.171.1243] [PMID: 9196156]
[http://dx.doi.org/10.1200/JCO.2004.12.082] [PMID: 15365074]
[http://dx.doi.org/10.1200/JCO.2005.05.1490] [PMID: 16921047]
[http://dx.doi.org/10.1200/JCO.2010.28.1386] [PMID: 20606091]
[http://dx.doi.org/10.1056/NEJMoa1011923] [PMID: 21561347]
[http://dx.doi.org/10.1056/NEJMoa1304369] [PMID: 24131140]
[http://dx.doi.org/10.1200/JCO.2016.67.1412] [PMID: 27247222]
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[http://dx.doi.org/10.1158/2159-8290.CD-11-0242] [PMID: 22585996]
[http://dx.doi.org/10.1186/s12885-016-2671-9] [PMID: 27590845]
[http://dx.doi.org/10.18632/oncotarget.3143] [PMID: 25779664]
[http://dx.doi.org/10.1097/MPA.0000000000001484] [PMID: 32011536]
[http://dx.doi.org/10.2147/CMAR.S126073] [PMID: 28461766]
[http://dx.doi.org/10.21037/jgo.2016.01.03] [PMID: 27284481]
[http://dx.doi.org/10.18632/oncotarget.27518] [PMID: 32206189]